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Immunization of mice for contact sensitivity induces two 
different antigen-specific Thy-l + cell activities that are re-
quired to act in seq~e.nce for elicitation of contact sensi~i:,i~ . 
In this study, 2,4-dmltro-l -fluorobenzene contact senSItIvIty 
responses in BALB/c and C3H/He mice demonstrated the 
importance of early-acting and antigen-specific contact 
sensitivity - initiating cells to recruit the classical, late-acting 
contact sensitivity effector T cells. Employing ill vitro treat-
ment of sensitized cells with monoclonal antibodies to cell 
surface determinants and then incubation in complement, 
prior to . adoptive cell transfer, the contact sensitivity-
initiating cells were sho:wn to hav.e a surface .ehenotype that is 
quite unusual for antigen-specIfic c~lls lThy-l +, ~I?~+, 
CD3-, CD4-, CDS-, sIg-, B220+, major hlstocompatibilIty 
complex class 11-, CD23+, IL-2R-, IL-3R+, Mel-14-, 
CD44+ (Pgp-l+), Jlld+ (HSA+), MAC-l+, LFA-l+, and 
FcyIlR+], and is quite different from the late-acting, contact 
sensitivity-effector T cells (Thy-l+, CD5+, CD3+, CD4+, 
CD8-, slg-, B220-, major histocompatibility complex class 
I n prior studies of contact sensitivity (CS) in mice, it was shown that two different antigen-specific Thy-l+, Ly-l+ (CDS+), Ly-2- (CD8-) cells are necessary for elicitation of this form of delayed-type hypersensitivity (DTH) [1-7] . These studies indicated that CS responses were due to an 
obligate sequential action of separate early-acting CS-i~/itiating cells, 
and late-acting CS-q[ector T cells. These prior studies of DTH ini-
tiation were confined almost entirely to the study of picryl chloride 
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11-, CD23-, IL-2R+, IL-3R-, and CD44- (Pgp-l-), Jlld-
(HSA-), MAC-l-, LFA-l+, FcyIIR-). Contact sensitivity in-
itiation was required for elicitation oElate 24-h 2,4-dinitro-l-
fluorobenzene contact sensitivity responses, in both BALB/c 
and C3H/He mice. Moreover, relatively high doses of some 
monoclonal antibodies [anti-B220 (CD45RA) and anti-
CD23 (lgE Fcell receptor)] were necessary to completely 
eliminate all contact sensitivity - initiating cells that permit-
ted expression oflate contact sensitivity - effector T-cell ac-
tivity. In contrast, high doses of monoclonal antibody spe-
cific for surface determinants of late-acting contact sensitiv-
ity effector T cells (anti-CD3 and anti-CD4), when used in 
high doses similar to anti-B220 and anti-CD23, had no effect 
on contact sensitivity - initiating cell activity. Our results in-
dicate that two very different antigen-specific Thy-l + cells 
are necessary to elicit 2,4-dinitro-l-fluorobenzene contact 
sensitivity in BALB/c and C3H/He mice. ] Illvest Dermatol 
102:321-327, 1994 
(PCl) and oxazolone (OX)-specific CS responses in CBA (H-2k) 
mice. 
DNFB (2,4-dinitro-l-fluorobenzene) is a contact-sensitizing an-
tigen that also is used commonly for experimental studies of CS 
[8 -11]. DNFB CS responsiveness is known to be controlled by the 
I-A region of H-2, the major histocompatibility complex of mice 
[8 -11]. BALB/c and C3H/He mice show a high level of respon-
siveness to DNFB CS. Therefore, we conducted the present study to 
determine whether CS-initiating cells also were important in the 
DNFB CS system ofBALB/c (H_2d) mice compared to C3H/He 
(H-2k) mice. We also determined the phenotypic characteristics of 
CS-initiating cells to further clarify the role of CS-initiating cells in 
this widely used DNFB antigen-specific contact-sensitivity system. 
MATERIALS AND METHODS 
Mice BALB/c and C3H/He mice were purchased from Shizouka Labora-
tory Animal Center, Ltd. (Hamamatsu, Japan). Eight- to fifteen-week-old 
female mice were used. The mice were rested at least 2 to 4 weeks before use 
in the animal center at Yokohama City University School of Medicine. 
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Antigens DNFB was purchased from Sigma Chemical Co. (St. Louis. 
MO) . Oxazolone (OX) was purchased from Aldrich Chemical Co. (Mil-
waukee. WI). 
Antibodies Monoclonal (MoAb) Thy-1.2-specific. Lyt-l.l (CD5)-
specific. Lyt-1.2 (CD5) -specific. Lyt-2.1 (CD8a)-specific. Lyt-2.2 
(CD8b) -specific. and L3T4 (CD4)- specific antibodies were purchased 
from Cedarlane Laboratories. Ltd. (Hornby. Ontario. Canada). MoAbs to 
CD3. B220 (CD45RA). and CD23 (IgE FceII receptor). FcyIIR (2.4G2). 
and I_Ad (AMS-32. 1) were purchased from PharMingen (San Diego. CAl. 
Goat anti-mouse IgG and IgM (Cappel. West Chester. PAl also were used. A 
rat IgM MoAb (anti - Aic-2) against the murine IL-3 receptor (IL-3R) [1 2] 
was a gift from Dr. S. Yonehara. Metropolitan Institute. Tokyo. Japan. 
Supernatant forms of MoAb Mel-14. Pgp-l (CD44) . IL-2R (7D4). Jl1d 
[heat stable antigen (HSA)]. and MAC-l (Ml/70) were kind gifts from Dr. 
Y. Aihara, Yokohama City U niversity. Yokohama, Japan. Supernatant con-
ta ining MoAb to LFA-l was kindly given by Dr. M. Minami. Yokohama 
City University, Yokohama, Japan. 
Immunization and Elicitation of DNFB CS Mice were sensitized 
with 0.5% DNFB in 4: 1 acetone: olive oil by application of 25 III to the 
shaved abdominal skin and all four paws on two successive days (day 0 and 1). 
or with 3% OX in 4: 1 absolute ethanol: acetone by application of 150 III to 
the shaved abdominal skin and all four paws on day 0 only. Four or five days 
after the last application (day 5 for DNFB and day 4 for OX). the mice were 
challenged on the ears with 20 III of 0.2% DNFB. or with 0.8% OX in 4: 1 
acetone: olive oi l. CS responses were determined 2 and 24 h later by measur-
ing ear thickness with a Peacock dial-thickness gauge (Ozaki Co .• Tokyo. 
Japan). and were compared to ear thickness in similarly challenged non-im-
mune controls. The increment in ear-swelling thickness was expressed in 
units of 10-2 mm. 
Adoptive Transfer of CS Cells were collected from axillary and in-
guinal lymph nodes of sensitized mice on either day 5 or on day 2 after 
sensitization with DNFB. One volume of cell suspension (107 /ml) was 
incubated with the indicated Ilg per ml of antibody at 4 ° C for 45 min. Then. 
after two washes of the suspension. one volume (107/ml) oflow tox rabbit 
complement (Cedarlane) (diluted 1 : 4) was added and incubation was con-
tinued at 37"C for 1 h. The cells then were washed three times at 4°C with 
Hanks' balanced salt solution (HBSS). A suspension of 4 X 107 lymph node 
cells was injected intravenously into naive mice via the tail vein in a 0.5 ml 
volume ofHBSS. Twenty four hours after transfer. mice were challenged on 
the ears with appropriate antigen. 
Verification of cell depletion by fluorescence-activated cell sorter analysis 
of lymphoid cells after ill vitro treatment with MoAb plus complement was 
not performed because the proportion of cells with the phenotype ofDTH-
initiating cells was quite low (less than 1%). Also, it was judged to be very 
likely that itl vitro MoAb treatment. especially with non-complement fixing 
hamster MoAb [4.13]. although not resulting in complete depletion ill vitro, 
probably was followed after intravenous adoptive cell transfer. by depletion 
itl vivo due to the IgG MoAb coating and uptake via FcyR+ cells of the 
reticuloendothelial system of the recipients. 
Immunomagnetic Bead Separation ofT Cells One hundred million 
DN FB CS effector lymph node cells were incubated with 200 III biotin-con-
jugated anti-CD4 MoAb (anti-L3T4) (PharMingen. San Diego. CAl. for 10 
min on ice. After washing with phosphate-buffered saline (PBS) containing 
1 % bovine serum albumin (BSA). the cells were resuspended in 400 III 
fluorescein isothiocyanate (FITC)-avidin (Becton Dickinson) plus 10 ml 
PBS and held for 10 min on ice. Then the cells were washed with PBS and 
incubated on ice for 5 min with Sill biotinylated magnetic beads in 500 It! 
PBS. After washing with PBS 1 % BSA. a stainless steel wool- filled separa-
tion column was placed in the magnetic field of the MACS apparatus (Bec-
ton Dickinson). The column had a capacity of about 108 cells (at 106 cells/ 
cm2) . For maximum depletion a slow flow speed of the cell suspension was 
adopted (approximately 0.3 ml/min) . The effiuent. negative (CD4- ) cells 
were collected with approximately three times the volume of the column. 
T he column was then washed using cold PBS 1 % BSA at four times the 
column matrix volume. with the flow speed increased to approximately 0.7 
ml/min. After removing the column from the magnetic field . the CD4 
positive cells were eluted with to ml PBS t % BSA. FACS analysis of sepa-
rated cells showed that the CD4+ cells contained 69% CD4+ cells. and the 
CD4- population contained 5% CD4+ cells. 
Statistics The results were expressed as means and SEM. Differences be-
tween experimental and control groups were determined using the Student t 
test and p < 0.05 was taken as the level of significance. 
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Day After Inilial CS 
Thai Mice Were Challenged Ear Swolllng(meon ± SEM X 10-- mm) 
Group On The Ears 
( ~fu~~Ce; ) 2hr 24hr Day 5 Day 2 Ear Challonge 0 2 4 6 8 10 0 2 4 6 8 
A (7) oNFB oNFB "'H @H 
B (8) oNFB OX ill * 111* 
C(7) oNFB oNF8 ;;; 'H 111* 
0(8 ) oNFB OX 1§11* i!1* 
E (5) DNF8 [11* ~ 
Figure 1. Antigen specificity of the early and late components ofDNFB CS 
inBALB/c mice. Mice in gronps A to D were sensitized by contact painting 
WIth 0.5% DNFB on days 0 and 1. and mice in group E were not sensitized. 
We attempted to elicit CS responses in either day 2 immune mice (third 
column) or day 5 immune mice (second column). This represented respec-
tively. day t (group c versus D). or day 4 (group A versus B) after completion 
of sensitization. T hus. the second and third columns from the left denote the 
day after initial CS that the mice were challenged on the ears. and the fourth 
column denotes the particular contactant (DNFB versus OX) used for chal-
lenge. to determine antigenic specificity of the responses. Control unsensi-
tized mice in group E were non-immunized cohorts of the other mice. and 
were challenged with 0.5% DNFB at the same time as groups A and C. on 
day 2 followin g initial sensitization of the other groups. The results of a 
similar group of nonimmune controls challenged on day 5 after immUJ1iza-
tion had similar responses to group E. and are not shown .• p < 0.005 group 
A at 2 and 24 h. and group C at 2 h. 
RESULTS 
Antigen (Ag) Specificity of the Early and Late Components 
ofDNFB CS in BALB/c Mice To test for Ag specificity of the 
early versus the late component ofDNFB CS inBALB/c mice, we 
challenged separate groups of sensitized mice on their ears with 
either DNFB or ox. As shown in Fig 1, the early 2-h ear swelling 
component ofDNFB CS was elicited 5 d (group A). or even as early 
as 2-d (group C). following the start of DNFB CS. In contrast. the 
classical late. 24-h component of CS was elicited by day 5 (group A). 
but not at day 2 (group C). The results in group A versus B. and in 
group C versus D, sho~ that the early-occurring 2-h ear swelling 
responses were Ag-speclfic because they were elicited in DNFB CS 
mice with DNFB. but were not elicited by ear challenge with OX. 
The late 24-h component of CS was also Ag-specific. Figure 2 
shows a reciprocal Ag specificity experiment. The early and late 
components of CS in OX sensitized BALB/c mice, which were 
challenged either with ox or DNFB on day 4, or as early as day 1, 
also were antigen-specific. Therefore, we concluded that antigen-
specific 2-h ear-swelling responses in BALB/c mice were "early" in 
two ways: 1) they were present early after CS (1- 2 d, i.e .• the 
responses were early occurring after sensitization). and 2) the cells 
mediating these responses led to elicitation of ear-swelling re-
sponses that occurred early after local challenge (i .e .• 2 h, thus th e 
cells were early acting). 
As a further test of Ag specificity of the unusual early 2-h ear-
swelling responses that were elicited 1 or 2 d after sensitization, we 
performed adoptive cell transfers. Figure 3 shows that transfer of 
DNFB CS cells led to the ability to elicit DNFB-specific 2-h re-
sponses (versus OX challenge) (group A versus B), and similarly 
transfer of OX-CS cells led to the ability to elicit OX-specific 2-h 
responses compared to DNFB challenge (group F versus G) . We 
concluded that elicitation of early 2-h ear-swelling responses was 
Ag-specific in actively sensitized mice (group C versus D; group H 
versus I). and. importantly, also in cell transfer recipients (group A 
versus B, and group F versus G). 
Surface Phenotype of Early and Late Effector Cells of 
DNFB CS We investigated the phenotype of cells responsible for 
the early and late components ofDNFB CS by adoptive transfer of 
ear-swelling responsiveness in syngenetic recipients oflymph node 
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Day Allcr Initial CS 
Thai Mice Were Ear Swelllng(Mean ± SEM X 1()-2 mm) 
Group Challenged On The Ears 2hr 
( ~,u:~; ) 24hr Doy 4 Day 1 Ear Challenge a 1 2 3 • 5 - I a 1 2 3 
" 
5 6 
A (6 ) OX OX bW WH 
B (5) OX ONFB ~ . ~ . 
C (6) OX OX • j-1 ~ . 
0(5) OX ONFB ~ * [}1. 
E (5) OX ~ . ~ . 
Figure 2. Antigen specificity of the early and late components of OX CS in 
BALBjc mice. Mice in groups A to D were sensitized by contact painting 
"With 3% OX on day 0, and mice in group E were not sensitized. We 
attempted to elicit CS responses in either day 1 immune mice (third colunU1) 
or day 4 immune mice (second column). This represented, respectively, day 
1 (group C versus D), or day 4 (group A versus B) after completion of 
sensi tization. Thus, the second and third columns from the left denote the 
day after initial CS that the mice were challenged on the ears, and the fourth 
column denotes the particular contactant (OX versus DNFB) used for chal-
lenge, to determine antigenic specificity of the responses. Control unsensi-
tized mice in group E were non-immunized cohorts of the other mice, and 
were challenged with 0.80/0 OX at the same time as groups A and C, on day 1 
following initial sensitization of the other groups. The results of a similar 
group of non-immune controls challenged 0 11 day 4 afte r immunization had 
similar responses to group E, and are not shown. • p < 0.005 group A at 2 
and 24 h, and group C at 2 h. 
cells (LNc) from BALBjc or C3HjHe mice that were sensitized 
w ith DNFB beginning S d previously. Sensitized LNC were treated 
in vitro with various MoAbs + C/, before begin transferred. As 
shown in Fig 4, treatment of sensitized BALBjc LNC with Thy-
1.2-specific MoAb (group B versus A), or CDS-specific MoAb 
(group C versus A), + C' abolished the ability to transfer e1ici-
Ear Donor Contact Sensiti -
za tion and Transfer Challenge Ear Swelllng(mean ± SEM X 10-2 mm) 
Group 2h 24h 
( ~,uM~C~ ) DayO Day1 Day2 Oay3 0 2 4 6 B 0 2 
A (5) DNFB DNFB transfer DNFB ~~ ~ 
B (5) DNFB DNFB transfer OX ~* ~ 
c (5) DNFB DNFB DNFB ~ ~ 
0(5) DNFB DNFB OX ~* i{I 
E (5) DNFB ~* I}I 
F (5) OX transfer DNFB 111 ** 1}1 
G (5) OX transfer OX ~ Ii 
H (5) OX DNFB 11< ** ~ 
(5) OX OX ~ 1:1< 
J (5) OX 1Il ** ~ 
DNFB- and OX ~immune C3H/ H e lymph node ce ll s were harvested after 
sensitization and transferred iv . Then recipient C3H / H e mice were 
cha llenged on the ears with 0 .2% DNFB or 0 .8% OX to e l ici t CS 
responses. No transfer w as performed in groups C. D . H . and I . 
* p < 0 .005 vs Groups A and C at 2hrs 
** P < 0 .005 vs Groups G and I at 2hrs 
Figure 3. Antigen specificity of the early 2-h component of DNFB and 
OX CS in C3HjHe mice sensitized 1- 2 d previously. Mice were sensitized 
by contact painting with 0.50/0 DNFB on days 0 and 1, and with 30/0 OX on 
day 1 or 2. DNFB and OX-immune C3HjHe lymph node cells were har-
vested on day 2 (DNFB) or day 1 (OX) after sensi tization and were trans-
ferred intravenously. Then some groups of activeIy sensitized mice (groups 
C and D; and groups H and I) , and the recipient C3HjHe mice (groups A 
and B; and groups F and G) were challenged on the ears with 0.20/0 DNFB or 
0.80/0 OX to elicit early CS responses at 2 h. • p < 0.005 group A versus B, or 
group C versus D. • P < 0.0005 group F versus G, and group H versus I, and 
group I versus J. 
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Ear Swelling(Mean ± SEM X 10- 2 mm) 
24hr 
o 2 4 6 8 10 
A (7) C alone ~
B (7) anti·Thy·1.2+ C 
C(7) anti·CDS+C 
D(7) anti·CDB+C 
E (7) anti·CD4+C 
F (7) anti·CDS + anli·CDB + C ~* 
G (6) anti·CD3 + C 
H (6) anti·lg + C 
-I (6) no transter(challenge alone) ~ * ~* 
Figure 4. Treatment of BALBjc DNFB CS effector cells with various 
MoAbs f>l~s complement. Lymph node cells of 5-d, DNFB-immune, con-
tact-senSItized BALBjc mice were incubated with the indicated monoclonal 
antibodies for 45 min at 4°C, and then with complement (C) for another 60 
min at 37"C. Then, after three washes, 4 X 107 lymph node cells were 
1l1Jected 1l1travenously 1I1tO naive syngeneic BALBjc mice. Then, after chal-
lenging recipients on the ears with 0.20/0 DNFB 1 d later, ear swelling was 
measured at 2 and 24 h with a microdial th ickness gauge. • p < 0.005 versus 
positive controls (group A). 
tation of the early component of ear swell ing. However, treatment 
of these CS LN C with CD8-specific, CD4-specific, CD3-specific, 
or Ig-specific antibodies, + C /, fai led to modify the early compo-
nent of CS (Fig 4, groups 0, E, G, and H). 
In contrast, the classical, 24-h late component of CS also was 
abolished by Thy-1.2-specific and CDS-specific MoAb, and 
in addition was abolished by CD4-specific and CD3-specific 
MoAb + C . These results indicated that in BALBjc mice, which 
were CS and challenged with DNFB, Thy-l+, CDS+, CD4-, 
CDS- , CD3- , and slg-, CS-initiating cells were responsible for 
transfer of the early, Ag-specific ear-swelling responses. Further, 
Thy-l+, CDS+, CD4+, CD8-, CD3+, sIg-, CS effectorTcells were 
respo~sible for the classical late 24-h ear-swelling responses. Similar 
adoptive transfer expenments using C3HjHe mice verified that the 
phenotype of the cells that mediated DNFB CS were the same as 
those for BALB/c mice (data not shown). 
TI~e experiments above employed a cell-separation procedure 
that l11vo.l~ed MoA~ binding to different cell surface antigens and 
then addition of lytiC C /, followed by in ,litro incubation at 37 °C, 
and then traJl5fer intravenously. To verify our findings using an-
other cell-separation procedure, we coated 5-d DNFB-sensitized 
~NC with ~iotin-cO!~ugated anti-CD4, and then, after washing, 
lllcubated With FITC-avidin and then separated the cells into CD4+ 
and CD4- populations with the MACS. By FACS analysis the 
CD4+ cells were 69% CD4+ and the CD4- cells were S% CD4+. 
Figure S shows that neither early nor late CS was detected with the 
CD4+ population (group B). In contrast, the CD4- cells had (as 
expected) no late CS activity, but early 2-h CS activity was retained 
(group C ). Furthermore, a mixing experiment combining the 
CD4+ and CD4- populations restored full CS activity (group D). 
Thus, this experiment showed that the CD4+ fraction that un-
doubtedly contained the late-acting, MHC class II-restricted CS 
effector T cells was unable to adoptively transfer 24-h CS, but when 
this population was combined with the CD4- fraction, which only 
expressed early CS activity, then the CS-initiating cells in the CD4-
population aided the CS-effector T cells in the CD4+ fraction to 
mediate fu ll CS responses. We concluded that immunomagnetic 
bead separation confirmed the findings obtained with MoAb + C' 
treatment. 
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Ear Swelling (Mean ± SEM X 10-2 mm) 
Group 
2 hr 24hr ! ~fu~~O: ) 
Ce ll Fraclion Obtained After 
I II V;,rO Treatme nt with 
anli ·CD4 M agnetic Beads o 2 4 6 8 10 0 2 4 6 8 10 
---------------------------
A(5) No treatment i\iH * 
-
tt?tl ~* 
6(5) C04 Positive Cells rn-t ~ 
C(5) C04 Negative Cells ! 1*1}1 
0(5) C04 ++ C04 - 11* @ "* 
No transfer ~ ~ (cha llenge a lone ) E(5) 
Figure 5. Separation ofBALB/c DNFB CS effector cells employing anti-
CD4 immunomagnetic beads. Five-day BALB/c DNFB-immunc lymph 
node cells wcre treated with biotin-conjugated anti-CD4 and then with 
FITC-avidin. Then the avidin-coated cells wcre treated with biotin-conju-
gated magnetic beads, and subsequently were processed on thc MACS sys-
tem of immunomagnetic bead separation. Resulting CD4+ and CD4- T 
cells were transferred intravenously into naive BALB/c mice eithcr alone or 
mixed together. Recipient native mice were challenged on the ears with 
0.2% DNFB 1 d after cell transfer . • p < 0.001/group E at 2 and 24 h. 
Effect of Anti-B220 MoAb Treatment on Early-Occurring 
and Early-Acting Cells Prior adoptive transfer experiments 
employing 4-d PCI and OX-sensitized CBA mice showed that the 
early component cells were depleted by anti-B220 (CD45RA) 
MoAb, but that the late 24-h cells were not affected [1,2]. There-
fore, in our studies of DNFB immunized BALB/c (Fig 6) and 
C3H/He mice (data not shown) , we studied the effect of anti-B220 
MoAb + C on the isolated early component cells that were present 
2 d after initial se~sitization . After treatment in vitro with MoAb + 
C', the early component cells were injected intravenously into naive 
recipients that were then challenged on the ears 1 d later. As shown 
in Fig 6, the early-occurring and early-acting cells in the 2-d im-
mune population were sensitive to treatment with C' and anti-B220 
MoAb at doses of 125 J1.g and 50 J1.g/107 cells/m\. However, a 
moderate increment of early ear swelling was detected in recipients 
of cells treated with a lower concentration of anti-B220 (25 J1.g/107 
cells/ml) and C'. In contrast to the early occurrence after immuni-
zation of the CS-initiating cell response, there were no 24-h late-
occurring CS responses in recipients of the 2-d DNFB-immune 
cells (Fig 6, group A) . Thus, complete abrogation of the early 2-h 
ear-swelling reactivity that was transferred by 2-d DNFB-sensitized 
LNC required a dose of anti-B220 MoAb of at least 50 J1.g/107 
cells/m\. 
Treatment of Early-Acting Ear Swelllng(Mean ± SEM X 10-* mm) 
Group Donor Contoct Lymph Node Colis 
( NUmber) Sensitization at 101 / ml 2hr 24hr 
of Mice (Day 0 & 11 (Harvested on Day 2) 0 I 1 3 4 5 6 J -1 - I 0 1 1 3 
A (61 ONFB C alone ~ 
B (61 ONFB anti·B220 (25.ttg/ml)+C ~ \** H 
C(61 ONFB antl·B220 {501' g/ml) + C ~* ~ 
0(61 ONFB anll·6220 (12S11-9/ ml) + C ~* H 
E (61 negative control ~* (}-I (challenge alone) 
Figure 6. Effect of Anti-B220 (CD45RA) MoAb treatment on the adoptive 
cell transfer of the early component ofDNFB CS in BALB/c mice. DNFB-
immune BALB/c lymph node cells were harvested 2 d after beginning the 
sensitization and then were incubated with different doscs of anti-B220 
antibody (/lg MoAb/107 cells/ml). Then the cells were transferred intra-
venously and recipients were challenged as before . • p < 0.005 versus group 
A at 2 h .•• p < 0.094 versus group A at 2 h. p values were not significant for 
2-h responses of group C versus group E. 
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MAb Treatment 01 5 day 
DNFB-Immunc lymph 
Node Cells In VItro 
A (6) C Alone 
B (6) C Alone 
Early -Act ing 
Lymph Node Cells 
Added 10 Transfer 2hr 24hr 
(H. ,"cslod : ' day 21 ;' ;';' I' Hf' ~'~' ___ -'-L _- _ '--'_ -_ ~-_-'+:...._ ....:_ ~ 
- - C (6' - - - - - - 82-20 (25': 9)+-C- - - - - - - - - - - -~. ~ 
___ D_(~) ________ ~23~ ~2~~t~I ~ : __ __ ____ + ______ k _ _ _ _ ~ _______ __ _ 
E (6 ) 8 220 (l 25J,lg )+ C 
F (6 ) 8220 (1 25,I Q)+ C + 
.- --------------------------------- --
G(6) 
H 16) 
I (61 
J 161 
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Figure 7. Sensitivity of DNFB-immune early-acting CS-initiating cells to 
differen~ doses of anti-B220 and anti-CD23 MoAbs. Five-day BALB/c 
DNFB-lmmune lymph node cells were treated with different doses of anti-
:6220, anti-CD23, or anti-IL-3R (/lg/107 cells/ml) plus complement (C). 
Then these cells were transferred intravenously either alone into naive-mice 
or mixed with early-acting lymph node cells from 2-day DNFB sensitized 
donors. Recipient naive mice were challenged on the ears with 0.2% DNFB 
1 d after transfer. •• p < 0.01 group M versus group A at 24 h. • p < 0.005 
versus group A. • P < 0.005 group C versus group E at 2 h. • p < 0.005 
group M versus group N at 2 h. • p < 0.005 group E versus groups A, B, C, 
D, and F at 24 h. • p < 0.005 group I versus groups A, B, G, H, and J at 24 h. 
No significance, group G versus group I at 2 h. 
Effect of Anti-B220, Anti-CD23, and Anti-IL-3R MoAb 
Treatr.ne~t on CS-Initiating Cell Activity The prior experi-
ments III Fig 6 showed that the early component cells ofDNFB CS 
were B220+. We next designed experiments to test whether the 
13220+ early component cells were also responsible for initiation of 
CS; i.e., we determined whether these cells "complemented" the 
late-acting CS-effector T cells and thus were required for elicitation 
of the 24-h component of DNFB CS. Thus, we co-transferred 
HALB/c LNC that were harvested on day 5 after initial DNFB CS 
(as a source of CS-initiating and CS-effector T cells) in a mixture 
with 2-d DNFB-CS cells (as a source of CS-initiating cells alone). In 
the first co-transfer experiments, the 5-d sensitized LNC were 
treated in vitro with anti-B220, anti-CD23, or anti - IL-3R 
MoAb + C', and then were transferred alone, or were co-trans-
f~r~ed with 2-d DNFB-CS cells to reconstitute CS-initiating ac-
tiVity. 
As shown in Figure 7,125 J1.g/107 cells/ml of anti-B220 or anti-
CD23 MoAb completely inhibited the adoptive early and late ear-
swelling responsiveness in recipients of 5-d immune cells (groups E 
and I versus groups A and B). In contrast, when these 5d MoAb-
treated cells were co-transferred together with 2-d DNFB-immune 
LNC, there was reconstitution of the late CS T-cell activity re-
maining in the immune LNC following treatment with anti-B220, 
anti-CD23, or anti-IL-3R and C' (group E versus F, group I versus 
J, and group K versus L). Thus, in DNFB-CS BALB/c mice the 
early component B220+, CD23+, IL-3R+ cells were required for the 
elicitation of late 24-h responses and therefore were CS initiating. 
However, a moderate increment of early ear swelling was detected 
at a dose of 25 J1.g/107 cells/ml of anti-B220 (group C), or of anti-
CD23 (group G), compared to 125 J1.g/107 cells/ml (groups E and 
I). Furthermore, this small early response allowed expression oflate 
CS-effector cell activity that was equivalent to late responses in mice 
that received a co-transfer of untreated CS-initiating cells from day 
2 DNFB-CS donors, together with anti-B220-treated 7-d immune 
cells (group C versus D, and group G versus H). 
These experiments employed very high doses (125 J.lg/l07 cells/ 
ml) of anti-B220 or anti-CD23 MoAb, which were necessary to 
completely deplete CS-initiating activity. Thus, we performed con-
trol experiments with similar high doses of anti-CD4 and anti-CD3 
MoAb (125 J1.g/107 cells/ml) to determine the effects of high doses 
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Figure 8. Effect of anti-B220 (CD45RA) MoAb treatment on DNFB CS in 
BALBjc mice. Separate 5-d and 2-d DNFB-immune lymph node cells were 
treated itl l,itro with anti-B220 MoAb at various doses and then with comple-
ment (C). Then 4 X 107 lymph node cells of each cell type were injected 
intravenously alone, or as a mixture, into recipient BALBjc mice. After 
challenge, ear swelling was measured with a microdial thickness gauge at 2 
and 24 h. • p < 0.05 versus positive control, group C at 2 and 24 h. p < 
0.025 group B versus group e at 24 h. 
of these late CS effector cell-specific MoAb on the early CS-initiat-
ing activity. Higher doses of anti-CD4 or anti-CD3 had no effect on 
early, CS-initiating activity in 5-d DNFB immune cells, nor on 2-d 
DNFB-immune CS effector cells in which the lower doses (25 
pgJml) of anti-CD4 and anti-CD3 completely depleted late CS-
effector T-cell activity (data not shown). 
We concluded that treatment with adequate doses of anti-B220 
?r anti-CD23 ~ C' completely depleted CS-initiating cells,leaving 
Isolated late-actmg CS effector T cells that alone could not mediate 
24-h CS. We also concluded that the effect of these high doses of 
MoAb was not non-specific, because high doses of anti-CD4 or 
anti-CD3 did not affect CS-initiating cells, and the high doses of 
anti-B220 and anti-CD23 did not affect the remaining late-acting 
CS effector T cells. However, these remaining cells could mediate 
24-h CS when CS-initiating activity was reconstituted with 2-d 
immune cells that contained isolated CS-initiating cells. Most im-
portantly, relatively high doses of anti-B220 and anti-CD23 MoAb 
were needed to eliminate all CS-initiating cells, and therefore com-
pletely eliminate all CS-initiation, whereas similar high doses of 
anti-CD4 and anti-CD3 had no effect on the cell transfer of early 
CS-initiating activity. 
The experiments summarized in Fig S confirm that relatively 
high doses of anti-B220 MoAb were needed not only to totally 
eliminate early cell activity, but also to eliminate the required CS 
initiation. In these experiments the 5-d immune cells were treated 
only with a high dose (125 ,ug/107 cells/ml) of anti-B220 to com-
pletely eliminate early cell activity and therefore CS initiation. In 
contrast, the 2-d DNFB-immune cells that were used for reconsti-
tution of CS-initiation were treated with various doses of anti-B220 
MoAb. As was shown for early cell activity in 5-d immune cells (Fig 
7), we found that moderately high doses (50 and 125 ,ug/107 cells/ 
ml) of anti-B220 were needed to completely eliminate the CS-ini-
tiating activity by the early component cells in the 2-d immune 
population (i.e., the ability to complement isolated late CS-effector 
T -cell activity in 5-d immune cells). 
In summary, these results show that there needs to be a complete 
depletion of Ag-specific early CS-initiating cell activity that is 
present in either 5-d (Fig 7) or 2-d (Fig S) DNFB-sensitized cells, to 
achieve a lack of expression of remaining late CS T-cell activity. 
Furthermore, this late T-cell activity can be reconstituted with iso-
lated early-acting CS-initiating cells in the 2-d DNFB-immune 
LNC. Therefore, in the DNFB CS system of BALB/c and C3H/ 
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He mice, an early occurring (1 -2 d) , early-acting (2 h), Thy-1+, 
CD5+, CD3- , CD4-, CDS-, sIg-, B220+, CD23+, IL-3R+ CS-ini-
tiating ~ell is required for expression of the late-occurring (4-5 d), 
late-actmg (24-h) claSSical CS response that is mediated by Thy-1 +, 
CD5+, CD3+, CD4+, CDS-, sIg-, B220-, CD23-, IL-3R- classical 
CS. e~ector T c.ells. Furthermore, a small amount of CS-initiating 
a~tlVlty remalI~mg after lower and suboptimal doses of MoAb spe-
Cific for CS-mltlatlllg cells can suffice for CS-initiation, and there-
fore expression of late CS activity. 
Treatment ofDNFB CS Effector Cells With Various Other 
MoAb Plus C' Finally, we investigated several more surface 
~arkers that ?'light distinguish early-acting CS-initiating and clas-
Sical, late-ac.tI.ng effector T cells. As shown in Fig 9, treatment of 
DNFB-sensltlzed BALB/c LNC with MoAb to CD44 (Pgp-l), 
~SA (Jlld)~ ~C-1 , LFA-1 , or FcyIIR, plus complement, abol-
Ished the ~bIilty to transfer early 2-h ear-swelling responses and 
24-h swellmg responses. However, treatment of these LNC with 
MoAb to Mel-14, IL-2R, or MHC class II, + C', failed to modify 
th~ early con:ponent of DNFB adoptive CS responses in :aALB/c 
mice. Regardmg the 24-h responses, treatment ill vitro with MoAb 
to CD44 (Pgp-1), HSA (J11d), MAC-l, LFA-l, FcyIIR, Mel-14, 
and IL-2R, plus complement abolished the transfer of 24-h ear-
swelling responsiveness, but there was no effect on transfers with 
MoAb to MHC class II. 
As before, the instances in which a given MoAb abolished transfer 
of2-h and 24-h responsiveness could have been due to the fact that 
both the ~arly and the late-acting T cells were positive to the given 
phenotypic marker, or ~~st because the early cell was positive and 
the loss .o~ early cell actiVity prevented expression of remaining late 
cell actiVity. Thus, we co-transferred the 5-d DNFB-sensitized 
lymph node cells that were treated with each of these MoAbs + C' t~get~er wit~ u.n~re.ated 2-.d DNFB-immune cells to attempt recon~ 
stltutlon CS-1IlltIat1l1g activity. Figure 9 shows that when the 5-d 
DNFB-immune cells treated with MoAb were co-transferred to-
gether with 2-d, untreated DNFB-immune LNC there was recon-
stitution of ~4-h late CS T·cell activity remaini~g in the immune 
LNC f<;>llowmg treatment with eith~r anti-Pgp-1 (group C versus 
D), a~tI-J11d (group E versus F), antI- mAC-l (group G versus H), 
or antI-FcyRII (group K versus L) and C', but not with anti - LFA-1 
and C' (group I versus J). 
These .results suggested that the complete surface phenotype of 
early-actmg CS-initiating cells in DNFB CS was Thy-1+, CD5+, 
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Figure 9. Treatment of BALBjc DNFB es effector cells with various 
MoAbs Rlus complement. Lymph node cells of 5-d, DNFB-immune, con-
tact-sensitized BALBjc mice were incubated with the indicated monoclonal 
antibodies for 45 min at 4°C, and then with complement (C) for another 60 
~in at 37°C. Then after three washes, 4 X 107 lymph node cells were 
mJected mtravenously into naive syngeneic BALB/ c mice either alone or 
mixed with early-acting lymph node cells from 2-d DNFB-sensitized 
donors. Then, after challenging recipients 011 the ears with 0.2% DNFB 1 d 
later, ear swelling was measured at 2 and 24 h with a microdial thickness 
gauge. 
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CD3-, CD4- , CDS-, sIg-, B220+, class n-, CD23+, IL-2R- , IL-
3R+, Mel-14-, Pgp-1+,J11d+, MAC-1+, LFA-1+, and FcyIIR+; and 
the phenotype of classical late-acting CS effector T cells was Thy-
1+, CD5+, C03+, C04+, COS-, sIg-, B220- , class II- , C023-, 
IL-2R+, IL3R-, Mel-14+, Pgp-1- , Jlld-, MAC-1-, LFA-1+, and 
FcyIIR-. 
DISCUSSION 
The data presented in this study ofONFB CS responses in BALB/c 
and C3H/He mice demonstrate the importance of an early-occur-
ring (1-2 d after immunization), early-acting (2 h after skin chal-
lenge), Ag-specific CS-initiating celi that has an unusual and rare 
phenotype. This CS-initiating cell is required for the local extravas-
cular recruitment of classic C04+ effector T cells to mediate 24 h 
CS responses. Previous studies of the phenotype of CS-initiating 
cells have almost exclusively employed CBA mice sensitized with 
either PCl or OX [1-7]. The current study employed the widely 
used ONFB CS response in BALB/c and C3H/He mice and found 
the following: 1) CS-initiation is an Ag-specific, immediate-hyper-
sensitivity-like ear-swelling response that is present by 1- 2 d fol-
lowing sensitization; 2) CS-initiation is required for elicitation of 
late 24-h CS responses that cannot be elicited until 4 - 5 dafter 
sensitization; 3) the CS-initiating cells have an unusual phenotype 
for an antigen-specific cell, Thy-I+, C05+, C03-, CD4-, COS-, 
sIg- , B220+, class II-, IL-2R-, C023+, IL-3R+, Mel-14-, C044+ 
(Pgp-1+), Jlld+, MAC-l+, LFA-1+, FcyIIR+; 4) relatively high 
doses of anti-B220 and anti-C023 MoAb are necessary to com-
pletely eliminate all CS-initiating activity, because partial removal 
of CS-initiating cells allowed a small amount of CS-initiating activ-
ity to remain and this permitted expression of late CS effector T-cell 
activity; and 5) the CS-initiating cell is strictly Ag-specific in ac-
tively sensitized mice and in recipients of adoptive cell transfers, yet 
the cell and the Ag-binding, CS-initiating factor lack all determi-
nants of all molecules that are known to mediate Ag specificity, such 
as immunoglobulins or TCR [3,4,7]. 
In the present study, late-acting, CS-effector T cells were Thy-
1+, COS+, C03+, C04+, CDS-, sIg-, B220-, class-II-, CD23-, 
IL-2R+, IL-3R- , Mel-14+, Pgp-1-, J11d-, MAC-1- , LFA-l+, and 
FcyIIR-. This is the phenotype expected of the C04+, ap TCR+, 
Ag/MHC class II-specific, effector T cells that are known to medi-
ate the late, classical aspects of CS. In addition, the current study 
showed that the surface phenotype of both the early-initiating and 
the late-effector T cells in ONFB CS ofBALB/c and C3H/He mice 
were the same as in the PCI and OX antigen CS systems of CBA 
mice [4,5,7], and employing additional MoAbs defined several more 
phenotypic characteristics of both the CS-initiating and CS-effector 
T cells. Taken together, these results suggest that early-occurring, 
and early-acting CS-initiating cells of a similar phenotype are gen-
erally required for expression oflate effector T-cell activity in mur-
ine CS. 
Our current and past results suggest that CS-initiating celis, 
which have an unusual phenotype for an antigen-specific cell, pro-
duce soluble Ag-specific factors that circulate and then sensitize 
tissue mast cells [14 - 17] and perhaps platelets (Geba et ai, unpub-
lished). Following local Ag challenge, the local mast cells and plate-
lets release serotonin, enabling 5HT-dependent local leukocyte re-
cruitment [14 -1 7] , and subsequent local 5HT -dependent activa-
tion of the late-acting ap TCR+ C04+, CS effector T cells [IS]. 
The C023 positivity of CS-initiating cells demonstrated in this 
study is a new finding. C023, which is the low-affinity receptor for 
IgE (FCER2) is usually found on B cells and on follicular dendritic 
cells [19,20], but only on some T cells [IS,21 -23]. Furthermore, 
bone marrow-derived inflammatory leukocytes, such as eosino-
phils, macrophages, monocytes, and platelets, usually are also 
C023+ [IS-23]. 
Because CS-initiating cells have some B-cell markers (Thy-l+, 
C05+, B220+, Jl1d+), and also have macrophage markers (MAC-
1 +, FcyRII+, F4S0+, and interferon-y induced class II expression) 
[24], the presence of C023 on CS-initiating cells may reflect either 
or both aspects of these cells. The finding that CS-initiating cells are 
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CD23+ provides further evidence that these unique Ag-specific 
celis, which are required for elicitation of late classical cutaneous 
T-cell responses in vivo, actually express many B-cell and macro-
phage markers [7,25]. Co-expression of B-cell and macrophage 
markers has been reported previously [26 - 2S] . 
The demonstration in this study that the CS-initiating cell is 
Pgp1+ (CD44+) and Jl1d+ [heat-stable antigen (HSA+)], whereas 
the late-acting, CS-effector T cell is C044- (Pgpl-) and Jlld-
(HSA - ) suggests that the Ag-specific CS-initiating cell is a primitive 
immune cell that derives from the lymphoid lineage, because both 
itl1ll1ature T cells and immature B cells are Jl1d+ (HSA+), and 
Pgp1 + [29,30]. The function of the HSA molecule on CS-initiating 
cells is unknown. Also, the current study confirmed that the CS-ini-
tiating cell is IL-3R+ and IL-2R- [7] , and it is known that primitive 
T or B cells express IL-3R and not IL-2R, whereas mature T and B 
cells express IL-2R and not IL-3R [31- 33]. Finally, we found that 
the CS-initiating cells are negative, whereas the CS-effector T cells 
are positive for binding by the MoAb Mel-14 that recognizes the 
lymphocyte homing receptor (gp90, LECAM-l) which governs the 
initial interactions of circulating lymphocytes with corresponding 
endothelial cell surface molecules, leading to local extravascular 
cellular recruitment. It is known that the CS-initiating cells do not 
need to recirculate to perform their function. CS-initiating cells are 
confined to the lymphoid tissues, from where they release soluble, 
Ag-specific, CS-initiating factors [16,17,25] . These factors recircu-
late and sensitize perivascular mast cells for subsequent release of 
5f1T which mediates the final non-specific vasoactive step in CS-
initiation. In contrast, late-acting, CS-effector T cells must recircu-
late and probably require Mel-14 expression to be recruited into the 
eJ{travascular space to be activated locally by antigen-presenting 
cells and by 5HT [34]. 
We also have shown previously that low doses of monoclonal IgE 
antibodies also could initiate CS responses [14]. These studies 
showed that small doses of anti-TNP IgE (1 ,ug/mouse), or small 
doses of 5HT (50 to 500 ng locally), which mediate small, immedi-
ate-occurring ear-swelling responses, were found to be optimal for 
DTH initiation. However, even lower doses ofIgE (10 ng/mouse), 
or of 5HT (5 ng locally), which did not mediate macroscopically 
measurable immediate responses, also were capable of OTH initia-
tion [14]. 
These prior results suggest an explanation for our finding in the 
current study of a requirement for large doses of some MoAb (anti-
B220 or anti-C023) to completely deplete CS-initiating cells. 
Thus, the large doses of MoAb needed to fully eliminate CS-initiat-
ing activity probably indicate that a 90 - 95% elimination of CS-ini-
tiating cells may not suffice for abrogation of CS initiation. In 
adoptive cell transfers in which cells were treated with lower doses 
of these MoAbs, some CS-initiating cells probably survived itl vitro 
cytolysis due to MoAb and C/, and subsequent in vivo, Fc receptor-
dependent clearance by the reticuloendothelial system. Thus, these 
few remaining CS-initiating cells may have provided a small 
amount of CS-initiating activity that was sufficient to allow for 
eJ{pression of late CS responsiveness. 
Local mast cells and platelets are the possible sources of 5HT in 
CS [14-17,25] . Our data indicate that early CS-initiating cells act 
by stimulating local release of 5-HT. Thus, mast cell activation via 
small doses ofIgE or injections of small doses of 5-HT suffice for CS 
initiation and recruitment of late-occurring effector T cells [14]. 
The early-acting CS-initiating cells finally were sensitive to anti-
B220 or anti-CD23 at a dose of 125 ,ug/l07 cells/ml. However, it is 
important to point out that the late-acting classical CS-effector T 
cells were resistant to anti-B220 or anti-C023, even at these higher 
doses. Furthermore, high doses (125 ,ug/l07cells/ml) of anti-C03 
or anti-C04 MoAb obviously abolished late CS effector cel l activ-
iry, but had no effect on early-acting CS-initiating cells, and the 
high doses (125 ,ug/107 cells/ml) of anti-B220 and anti-C023 had 
no effect on the late-acting CS-effector T cells. Thus, the effects of 
high doses of anti-B220 and anti-C023 on the CS-initiating cells 
was not non-specific. 
In conclusion, the results of this study are important in several 
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respects. They show that 1) CS initiation is an A.g-speci~c.ear~sw~l­
ling response that IS present by 1-2 d followll1g sensItization In 
several CS systems; 2) CS initiation is required for elicitation oflate 
24-h CS responses that cannot be elicited until 4 - 5 d after sensitiza-
tion; and 3) CS-initiating cells have an unusual phenotype, Thy-1+, 
CD5+, CD3-, CD4-, CDS-, sIg-, B220+, class-II-, CD23+, IL-
2R-, IL-3R+, Mel-14-, Pgp-1+, Jlld+, MAC-I+, LFA-1+, and 
FcyIIR+. 
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